



ASX Release

Thursday 4 July 2024

Successful completion of \$1.9m capital raise

Compumedics raises \$1.9m to underpin execution of global Home Sleep Test (HST) Software as a Service (SaaS) strategy

Compumedics Limited (ASX: CMP), a global medical device company that develops, manufactures, and commercialises diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring, is pleased to announce that it has successfully completed a \$1.9m capital raise, which was announced to market on 2nd July 2024.

Dr David Burton, Executive Chairman of Compumedics, said:

“We are very pleased with the level and quality of support shown for the Company by this capital raising. We are also very grateful to our long-term supporting shareholders and delighted to welcome our new shareholders onto the share register. This placement strengthens our balance sheet, providing greater flexibility to pursue our global Somfit, home sleep testing (HST) strategy & rollout, with the particular focus on the USA, where we recently announced (ASX, 17 June 2023) the appointment of Craig Gallivan as National Vice President of Sales – Home Sleep Testing.

Use of Funds

The Company confirms the use of funds as set out below:

- (a) The employment of up to 6 additional sales staff in the USA, over the next 6 months approximately, who will report directly to the newly appointed Vice President of Sales – Home Sleep Testing, for the development of the Somfit home sleep test business there, including specific sales goals aligned with their territories as they are onboarded; and
- (b) Additional working capital to support the increased sales to be generated by the new sales staff mentioned above, including the ramp up in the volume of Somfit devices manufactured and the associated resources required to deliver this.

Capital Raising Details

Compumedics received binding commitments for a Placement to professional and sophisticated investors, comprising of 6,785,715 new fully paid ordinary shares in the Company (**Placement Securities**) at an issue price of \$0.28 to raise approximately \$1.9m (before costs) (**Capital Raising**). The Placement price of \$0.28 per share represents a 10% discount to the 15-day VWAP immediately prior to the trading halt.

The placement was well supported by new and existing institutional, professional and sophisticated investors.

The Directors of the Company have committed to subscribe for \$50,000 in the Placement.

The issue of shares will be completed under the Company's LR7.1 placement capacity and approval under ASX Listing Rule 10.11 for Director participation. The issue of shares to Directors is subject to shareholder approval at the Company's upcoming AGM in October 2024.

PAC Partners Securities Pty Ltd acted as sole lead manager for the capital raising and will be paid fees on normal commercial terms, which is up to 6% of the value of the new securities issued.

The Company will announce a Notice of Annual General Meeting to approve the issue of placement securities to Directors.

About Compumedics Limited

Compumedics Limited [ASX: CMP] is a medical device company that develops, manufactures, and commercialises diagnostic technology for sleep, brain, and ultrasonic blood flow monitoring applications. The Company owns Neuroscan, based in the US, and DWL Elektronische GmbH, based in Germany. In conjunction with these two subsidiaries, Compumedics has a broad international reach, including the Americas, Australia and Asia Pacific, Europe, and the Middle East.

Executive Chairman Dr. David Burton founded Compumedics in 1987. The same year, the Company successfully designed and installed the first fully computerised Australian sleep clinic at Epworth Hospital in Melbourne. Following this early success, Compumedics focused on developing products for the growing international sleep clinic and home monitoring markets.

Compumedics listed on the Australian Securities Exchange in 2000. Over the years, Compumedics has received numerous awards, including Australia's Exporter of the Year, and has been recognised as a Top 100 Innovator by both German and Australian Governments.

For further information, please contact:

Dr. David Burton
Executive Chairman, CEO
P: +61 3 8420 7300
F: +61 3 8420 7399

David Lawson
Director, CFO
P: + 61 3 8420 7300
F: +61 3 8420 7399

Authorised for lodgement by Compumedics Limited's Board of Directors